Targeting Phospho-Ser422 by Active Tau Immunotherapy in the THYTau22 Mouse Model: A Suitable Therapeutic Approach

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.

Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,007 · see citing works

Transmission and spreading of tauopathy in transgenic mouse brain

Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803 · see citing works

Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils

Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · see citing works

Propagation of Tau Misfolding from the Outside to the Inside of a Cell

Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252 · see citing works

Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease

Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998 · see citing works

Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein

Allen, B., Ingram, E., Takao, M., Smith, M. J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P. C., et al. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09340.2002 · Cited by 746 · see citing works

Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L)

Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702 · see citing works

Glucocorticoids increase amyloid-β and tau pathology in a mouse model of alzheimer’s disease

Green, K. N., Billings, L. M., Roozendaal, B., McGaugh, J. L., & LaFerla, F. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2797-06.2006 · Cited by 623 · see citing works

Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau.

Matsuo, E. S., Shin, R., Billingsley, M., de Voorde, A. V., O'Connor, M., Trojanowski, J., & Lee, V. (1994) · Neuron · doi:10.1016/0896-6273(94)90264-x · Cited by 588 · see citing works

-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin

Ma, Q.-L., Yang, F., Rosario, E. R., Ubeda, O. J., Beech, W., Gant, D. J., Chen, P. P., Hudspeth, B., Chen, C., Zhao, Y., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1071-09.2009 · Cited by 536 · see citing works

Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms

Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4637-04.2005 · Cited by 511 · cited 1× · see citing works

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works

Getting into the Brain

Patel, B. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2008) · CNS Drugs · doi:10.2165/0023210-200923010-00003 · Cited by 466 · see citing works

Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits

Schindowski, K., Bretteville, A., Leroy, K., Bégard, S., Brion, J., Hamdane, M., & Buée, L. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060002 · Cited by 396 · see citing works

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

Chai, X., Wu, S., Murray, T. K., Kinley, R. D., Cella, C. V., Sims, H., Buckner, N., Hanmer, J. M., Davies, P., O’Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 346 · see citing works

Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau Pathology

Polydoro, M., Acker, C. M., Duff, K., Castillo, P. E., & Davies, P. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1065-09.2009 · Cited by 329 · see citing works

Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · see citing works

Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model

Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272 · see citing works

A Conformation‐ and Phosphorylation‐Dependent Antibody Recognizing the Paired Helical Filaments of Alzheimer's Disease

Jicha, G. A., Lane, E., Vincent, I. J., Ötvös, L., Hoffmann, R., & Davies, P. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69052087.x · Cited by 264 · see citing works

Active and passive immunotherapy for neurodegenerative disorders

Brody, D. L., & Holtzman, D. M. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125529 · Cited by 250 · see citing works

Extracellular tau is toxic to neuronal cells

Gómez-Ramos, A., Díaz-Hernández, M., Cuadros, R., Hernández, F., & Avila, J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.07.078 · Cited by 241 · see citing works

Tauopathy-like Abnormalities and Neurologic Deficits in Mice Immunized With Neuronal Tau Protein

Rosenmann, H., Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., & Abramsky, O. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1459 · Cited by 178 · see citing works

Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice

Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., & Rosenmann, H. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.010 · Cited by 174 · see citing works

Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo

Guillozet-Bongaarts, A. L., Cahill, M. E., Cryns, V. L., Reynolds, M. R., Berry, R. W., & Binder, L. I. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03784.x · Cited by 169 · see citing works

Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology

Bélarbi, K., Burnouf, S., Fernández-Gómez, F.-J., Laurent, C., Lestavel, S., Figeac, M., Sultan, A., Troquier, L., Leboucher, A., Caillierez, R., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.04.022 · Cited by 162 · see citing works

Characterization of mAb AP422, a novel phosphorylation‐dependent monoclonal antibody against tau protein

Hasegawa, M., Jakes, R., Crowther, R. A., Lee, V. M.-Y., Ihara, Y., & Goedert, M. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00271-2 · Cited by 156 · see citing works

Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice

Leroy, K., Bretteville, A., Schindowski, K., Gilissen, E., Authelet, M., De Decker, R., Yilmaz, Z., Buée, L., & Brion, J.-P. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.070345 · Cited by 135 · see citing works

Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility

Sahara, N., Lewis, J. M., Deture, M. A., McGowan, E. M., Dickson, D. W., Hutton, M., & Yen, S.-H. C. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01241.x · Cited by 127 · see citing works

Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease

Yanagisawa, M., Planel, E., Ishiguro, K., & Fujita, S. C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01480-5 · Cited by 123 · see citing works

Tau as a Biomarker of Neurodegenerative Diseases

Schraen‐Maschke, S., Sergeant, N., Dhaenens, C., Bombois, S., Deramecourt, V., Caillet‐Boudin, M., Pasquier, F., Maurage, C., Sablonnière, B., Vanmechelen, E., et al. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.4.363 · Cited by 121 · see citing works

Phosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice

Grueninger, F., Bohrmann, B., Czech, C., Ballard, T. M., Frey, J. R., Weidensteiner, C., von Kienlin, M., & Ozmen, L. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.09.004 · Cited by 117 · see citing works

Immunotherapy Targeting Pathological Tau Protein in Alzheimer's Disease and Related Tauopathies

Sigurdsson, E. M. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-15202 · Cited by 116 · see citing works

Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration

Bussière, T., Hof, P. R., Vanbesien-Mailliot, C., Brown, C., Caillet‐Boudin, M., Perl, D. P., Buée, L., & Delacourte, A. (1999) · Acta Neuropathologica · doi:10.1007/s004010050978 · Cited by 102 · see citing works

Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission

der Jeugd, A. V., Ahmed, T., Burnouf, S., Bélarbi, K., Hamdame, M., Grosjean, M., Humez, S., Balschun, D., Blum, D. L., Buée, L., et al. (2010) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2010.12.005 · Cited by 98 · see citing works

Tau as a Therapeutic Target for Alzheimers Disease

Boutajangout, A., Sigurdsson, E. M., & Krishnamurthy, P. K. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717195 · Cited by 97 · see citing works

Divergent phosphorylation pattern of tau in P301L tau transgenic mice

Deters, N. A., Ittner, L. M., & Götz, J. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06318.x · Cited by 89 · see citing works

Murine models of Alzheimer's disease and their use in developing immunotherapies

Wısnıewskı, T., & Sigurdsson, E. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.05.004 · Cited by 80 · see citing works

Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies

A. Lasagna-Reeves, C., L. Castillo-Carranza, D., R. Jackson, G., & Kayed, R. (2011) · Current Alzheimer Research · doi:10.2174/156720511796717177 · Cited by 80 · see citing works

Phosphorylation of microtubule‐associated protein tau by stress‐activated protein kinases in intact cells

Buée‐Scherrer, V., & Goedert, M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02460-2 · Cited by 76 · see citing works

Role of Phosphorylation in the Conformation of τ Peptides Implicated in Alzheimer's Disease

Daly, N. L., Hoffmann, R., Otvos, L. J., & Craik, D. J. (2000) · Biochemistry · doi:10.1021/bi0004807 · Cited by 75 · see citing works

C‐terminal truncation modulates both nucleation and extension phases of τ fibrillization

Yin, H., & Kuret, J. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.11.077 · Cited by 68 · see citing works

Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies

Ferrer, I., Hern�ndez, I., Boada, M., Llorente, A., Rey, M. J., Cardozo, A., Ezquerra, M., & Puig, B. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0756-4 · Cited by 67 · see citing works

Mechanisms of Aβ Plaque Clearance following Passive Aβ Immunization

Morgan, D. (2005) · Neurodegenerative Diseases · doi:10.1159/000090366 · Cited by 52 · see citing works

Vaccination as a Therapeutic Approach to Alzheimer's Disease

Wısnıewskı, T., & Boutajangout, A. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20156 · Cited by 51 · see citing works

Ubiquitin-negative mini-pick-like bodies in the dentate gyrus in p301l tauopathy

Ferrer, I., Hernández, I., Puig, B., Rey, M. J., Ezquerra, M., TOLOSA, E. S., & Boada, M. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2003-5604 · Cited by 25 · see citing works

Induction of a specific tau Alzheimer epitope in SY-5Y neuroblastoma cells

Caillet‐Boudin, M., & Delacourte, A. (1996) · Neuroreport · doi:10.1097/00001756-199612200-00061 · Cited by 16 · see citing works

Intra-peritoneal Injection of Polyclonal Anti-Interferon Alpha Antibodies Cross the Blood Brain Barrier and Neutralize Interferon Alpha

Sas, A. R., Jones, R., & Tyor, W. R. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9715-8 · Cited by 13 · see citing works

Active versus passive immunization against hepatitis A in the Israel defence forces: a cost–benefit analysis

Gillis, D., Yetiv, N., Gdalevich, M., Mimouni, D., Ashkenazi, I., Shpilberg, O., Eldad, A., & Shemer, J. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00091-8 · Cited by 11 · see citing works

Tau pathology and neurodegeneration

Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133 · see citing works

Tau-targeting therapies for Alzheimer disease

Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works

Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies

Šimić, G., Leko, M. B., Wray, S., Harrington, C. R., Delalle, I., Milošević, N. J., Bažadona, D., Buée, L., de Silva, R., Giovanni, G. D., et al. (2016) · Biomolecules · doi:10.3390/biom6010006 · Cited by 698 · see citing works

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574 · see citing works

Alzheimer disease therapy—moving from amyloid-β to tau

Giacobini, E., & Gold, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.223 · Cited by 483 · see citing works

Tau Aggregation and Its Interplay with Amyloid-β

Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359 · see citing works

Review on Alzheimer’s Disease: Inhibition of Amyloid Beta and Tau Tangle Formation

Ashrafian, H., Zadeh, E. H., & Khan, R. H. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.11.192 · Cited by 368 · see citing works

Propagation of Protein Aggregation in Neurodegenerative Diseases

Vaquer‐Alicea, J., & Diamond, M. I. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061516-045049 · Cited by 308 · see citing works

Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy

Laurent, C., Dorothée, G., Hunot, S., Martin, E., Monnet, Y., Duchamp, M., Dong, Y., Légeron, F.-P., Leboucher, A., Burnouf, S., et al. (2016) · Brain · doi:10.1093/brain/aww270 · Cited by 297 · see citing works

A walk through tau therapeutic strategies

Jadhav, S., Ávila, J., Schöll, M., Kovács, G. G., Kövari, E., Škrabana, R., Evans, L., Kontseková, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 286 · see citing works

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · see citing works

Tau-based therapies in neurodegeneration: opportunities and challenges

Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272 · see citing works

Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody

Luo, W., Liu, W., Hu, X., Hanna, M., Caravaca, A., & Paul, S. M. (2015) · Scientific Reports · doi:10.1038/srep11161 · Cited by 241 · see citing works

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259 · see citing works

Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies

Dujardin, S., Lécolle, K., Caillierez, R., Bégard, S., Zommer, N., Lachaud, C., Carrier, S., Dufour, N., Aurégan, G., Winderickx, J., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-14 · Cited by 259 · see citing works

Tau immunotherapy for Alzheimer's disease

Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works

Tau in neurodegenerative disease

Gao, Y.-L., Wang, N., Sun, F.-R., Cao, X.-P., Zhang, W., & Yu, J.-T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.23 · Cited by 222 · see citing works

Protein phosphorylation in neurodegeneration: friend or foe?

Tenreiro, S., Eckermann, K., & Outeiro, T. F. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00042 · Cited by 252 · see citing works

Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials

Mandler, M., Valera, E., Rockenstein, E. M., Weninger, H., Patrick, C., Adame, A., Santic, R., Meindl, S., Vigl, B., Smrzka, O. W., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1256-4 · Cited by 228 · see citing works

Ectosomes: A New Mechanism for Non-Exosomal Secretion of Tau Protein

Dujardin, S., Bégard, S., Caillierez, R., Lachaud, C., Delattre, L., Carrier, S., Loyens, A., Galas, M., Bousset, L., Melki, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100760 · Cited by 215 · see citing works

Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a mouse model of Alzheimer‘s disease

Collin, L., Bohrmann, B., Göpfert, U., Oroszlan‐Szovik, K., Ozmen, L., & Grüninger, F. (2014) · Brain · doi:10.1093/brain/awu213 · Cited by 203 · see citing works

Prion-like Properties of Tau Protein: The Importance of Extracellular Tau as a Therapeutic Target

Holmes, B. B., & Diamond, M. I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.549295 · Cited by 202 · see citing works

Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

Congdon, E. E., Gu, J., Sait, H. B. R., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.491001 · Cited by 195 · see citing works

Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology.

Laurent, C., Eddarkaoui, S., Derisbourg, M. J., Leboucher, A., Demeyer, D., Carrier, S., Schneider, M., Hamdane, M., Müller, C., Buée, L., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.027 · Cited by 189 · see citing works

From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy

Colin, M., Dujardin, S., Schraen-Maschke, S., Meno-Tetang, G., Duyckaerts, C., Courade, J.-P., & Buée, L. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02087-9 · Cited by 187 · see citing works

A2A adenosine receptor deletion is protective in a mouse model of Tauopathy

Laurent, C., Burnouf, S., Ferry, B., Batalha, V. L., Coelho, J. E., Baqi, Y., Malik, E. M., Mariciniak, E., Parrot, S., der Jeugd, A. V., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.151 · Cited by 188 · see citing works

Anti‐tau antibody reduces insoluble tau and decreases brain atrophy

Yanamandra, K., Jiang, H., Mahan, T. E., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.176 · Cited by 185 · see citing works

Tau passive immunization inhibits not only tau but also Aβ pathology

Dai, C., Tung, Y. C., Liu, F., Gong, C., & Iqbal, K. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0227-5 · Cited by 186 · see citing works

Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody

Albert, M., Mairet‐Coello, G., Danis, C., Lieger, S., Caillierez, R., Carrier, S., Skrobala, E., Landrieu, I., Michel, A., Schmitt, M., et al. (2019) · Brain · doi:10.1093/brain/awz100 · Cited by 177 · see citing works

Neurotoxicity and Memory Deficits Induced by Soluble Low-Molecular-Weight Amyloid- 1-42 Oligomers Are Revealed In Vivo by Using a Novel Animal Model

Brouillette, J., Caillierez, R., Zommer, N., Pires, C. A., Benilova, I., Blum, D. L., Strooper, B. D., & Buée, L. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.5901-11.2012 · Cited by 173 · see citing works

Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

Gu, J., Congdon, E. E., & Sigurdsson, E. M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494922 · Cited by 163 · see citing works

Tau Immunotherapy Modulates Both Pathological Tau and Upstream Amyloid Pathology in an Alzheimer's Disease Mouse Model

Castillo-Carranza, D. L., Guerrero-Muñoz, M. J., Sengupta, U., Hernandez, C., Barrett, A. D. T., Dineley, K., & Kayed, R. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4989-14.2015 · Cited by 149 · see citing works

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

Mandler, M., Valera, E., Rockenstein, E. M., Mante, M., Weninger, H., Patrick, C., Adame, A., Schmidhuber, S. M., Santic, R., Schneeberger, A., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0008-9 · Cited by 148 · see citing works

Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models

Sankaranarayanan, S., Barten, D. M., Vana, L., Devidze, N., Yang, L., Cadelina, G. W., Hoque, N., DeCarr, L. B., Keenan, S., Lin, A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125614 · Cited by 143 · see citing works

New Insights Into Drug Discovery Targeting Tau Protein

Soeda, Y., & Takashima, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.590896 · Cited by 133 · see citing works

Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies

Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132 · see citing works

Therapeutic strategies for tau mediated neurodegeneration

Yoshiyama, Y., Lee, V. M. ‐., & Trojanowski, J. Q. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303144 · Cited by 129 · see citing works

Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders

Valera, E., Spencer, B. J., & Masliah, E. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0397-z · Cited by 129 · see citing works

“Prion‐Like” Templated Misfolding in Tauopathies

Clavaguera, F., Lavenir, I., Falcon, B., Frank, S., Goedert, M., & Tolnay, M. (2013) · Brain Pathology · doi:10.1111/bpa.12044 · Cited by 129 · see citing works

Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology

Burlot, M., Braudeau, J., Michaelsen‐Preusse, K., Potier, B., Ayciriex, S., Varin, J., Gautier, B., Djelti, F., Audrain, M., Dauphinot, L., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv268 · Cited by 122 · see citing works

The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology

Cárdenas-Aguayo, M. D. C., Gómez-Virgilio, L., DeRosa, S., & Meraz-Ríos, M. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500148z · Cited by 120 · see citing works

New perspectives on the role of tau in Alzheimer's disease. Implications for therapy

Medina, M., & Ávila, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.013 · Cited by 118 · see citing works

Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease

Bulic, B., Pickhardt, M., & Mandelkow�, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3017317 · Cited by 116 · see citing works

Tau as a therapeutic target in neurodegenerative disease

Himmelstein, D. S., Ward, S., Lancia, J. K., Patterson, K. R., & Binder, L. I. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.001 · Cited by 113 · see citing works

Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease

Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., & Novak, M. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt277 · Cited by 112 · see citing works

Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease

Madav, Y., Wairkar, S., & Prabhakar, B. R. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.01.004 · Cited by 116 · see citing works

Alzheimer disease therapeutics: Focus on the disease and not just plaques and tangles

Iqbal, K., Liu, F., & Gong, C. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.002 · Cited by 110 · see citing works

Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity

Ando, K., Maruko-Otake, A., Ohtake, Y., Hayashishita, M., Sekiya, M., & Iijima, K. M. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005917 · Cited by 105 · see citing works

Tau-Based Therapeutics for Alzheimer’s Disease: Active and Passive Immunotherapy

Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0019 · Cited by 105 · see citing works

Advances and considerations in AD tau-targeted immunotherapy

Bittar, A., Bhatt, N. N., & Kayed, R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 105 · see citing works

Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome?

Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102 · see citing works

Tau-Based Therapeutic Approaches for Alzheimer's Disease - A Mini-Review

Boutajangout, A., & Wısnıewskı, T. (2014) · Gerontology · doi:10.1159/000358875 · Cited by 105 · see citing works

Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy

Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal2029 · Cited by 100 · see citing works

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

Panza, F., Solfrizzi, V., Imbimbo, B. P., Tortelli, R., Santamato, A., & Logroscino, G. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.883921 · Cited by 97 · see citing works

The Role of Tau in Neurodegenerative Diseases and Its Potential as a Therapeutic Target

Wolfe, M. S. (2012) · Scientifica · doi:10.6064/2012/796024 · Cited by 97 · see citing works

Current Status of Clinical Trials on Tau Immunotherapies

Ji, C., & Sigurdsson, E. M. (2021) · Drugs · doi:10.1007/s40265-021-01546-6 · Cited by 96 · see citing works

The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy

Zhang, C., Xing, A., Tan, M., Tan, L., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9415-8 · Cited by 91 · see citing works

Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures

Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91 · see citing works

Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease

Echeverrı́a, V., Iarkov, A., & Aliev, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.002 · Cited by 91 · see citing works

Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies

Dai, C., Chen, X., Kazim, S. F., Liu, F., Gong, C., Grundke, I., & Iqbal, K. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1315-y · Cited by 90 · see citing works

Tau immunotherapies: Lessons learned, current status and future considerations

Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90 · see citing works

Emerging Therapeutics for Alzheimer's Disease

Chiang, K., & Koo, E. H. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135932 · Cited by 88 · see citing works

Invited review: Animal models of tauopathies and their implications for research/translation into the clinic

Dujardin, S., Colin, M., & Buée, L. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12200 · Cited by 88 · see citing works

Tau‐targeting passive immunization modulates aspects of pathology in tau transgenic mice

Ittner, A., Bertz, J., Suh, L. S., Stevens, C. H., Götz, J., & Ittner, L. M. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12821 · Cited by 81 · see citing works

Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment

Danis, C., Dupré, E., Zejneli, O., Caillierez, R., Arrial, A., Bégard, S., Mortelecque, J., Eddarkaoui, S., Loyens, A., Cantrelle, F., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.009 · Cited by 73 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls1

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179937 · Cited by 76 · see citing works

Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future

Hampel, H. J., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S. S., & Lista, S. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 77 · see citing works

A critical appraisal of tau‐targeting therapies for primary and secondary tauopathies

Imbimbo, B. P., Ippati, S., Watling, M., & Balducci, C. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12453 · Cited by 72 · see citing works

Passive immunotherapy of tauopathy targeting pSer413‐tau: a pilot study in mice

Umeda, T., Eguchi, H., Kunori, Y., Matsumoto, Y., Taniguchi, T., Mori, H., & Tomiyama, T. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.171 · Cited by 73 · see citing works

Potential of the Antibody Against cis–Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury

Lu, K. P., Kondo, A., Albayram, Ö., Herbert, M. K., Liu, H., & Zhou, X. Z. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2027 · Cited by 74 · see citing works

Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species

Gerson, J. E., Castillo‐Carranza, D. L., & Kayed, R. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500143n · Cited by 73 · see citing works

Tau immunotherapies for Alzheimer’s disease

Hoskin, J. L., Sabbagh, M. N., Al-Hasan, Y. M., & Decourt, B. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1619694 · Cited by 68 · see citing works

Untitled work

(2013) · PubMed · Cited by 66 · see citing works

Update on tauopathies

Lebouvier, T., Pasquier, F., & Buée, L. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000502 · Cited by 68 · see citing works

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-189010 · Cited by 67 · see citing works

Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy

Blackmore, T., Meftah, S., Murray, T. K., Craig, P. J., Blockeel, A., Phillips, K., Eastwood, B., O’Neill, M. J., Marston, H., Ahmed, Z., et al. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0306-2 · Cited by 66 · see citing works

Antibody-DerivedIn VivoImaging of Tau Pathology

Krishnaswamy, S., Lin, Y., Rajamohamedsait, W. J., Rajamohamedsait, H. B., Krishnamurthy, P., & Sigurdsson, E. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2755-14.2014 · Cited by 62 · see citing works

A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease

Agadjanyan, M. G., Petrovsky, N., & Ghochikyan, A. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.06.1884 · Cited by 65 · see citing works

Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities

Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61 · see citing works

Tau neurotoxicity and rescue in animal models of human Tauopathies

Krüger, L., & Mandelkow, E. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.09.004 · Cited by 60 · see citing works

Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target

Oakley, S. S., Maina, M. B., Marshall, K. E., Al‐Hilaly, Y. K., Harrington, C., Wischik, C. M., & Serpell, L. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590754 · Cited by 57 · see citing works

Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies

Clavaguera, F., Grueninger, F., & Tolnay, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.037 · Cited by 60 · see citing works

Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66 · see citing works

Tau Immunotherapy

Sigurdsson, E. M. (2016) · Neurodegenerative Diseases · doi:10.1159/000440842 · Cited by 56 · see citing works

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Agadjanyan, M. G., Zagorski, K., Petrushina, I., Davtyan, H., Kazarian, K., Antonenko, M., Davis, J. L., Bon, C., Blurton-Jones, M. M., Cribbs, D. H., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0172-1 · Cited by 53 · see citing works

Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau

Strang, K. H., Goodwin, M. S., Riffe, C. J., Moore, B. D., Chakrabarty, P., Levites, Y., Golde, T. E., & Giasson, B. I. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0458-0 · Cited by 52 · see citing works

Highly specific and selective anti‐pS396‐tau antibody C10.2 targets seeding‐competent tau

Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. C. A., Egebjerg, J., Falsig, J., Helboe, L., Jul, P., Kartberg, F., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.005 · Cited by 51 · see citing works

Prophylactic Active Tau Immunization Leads to Sustained Reduction in Both Tau and Amyloid-β Pathologies in 3xTg Mice

Rajamohamedsait, H., Rasool, S., Rajamohamedsait, W., Lin, Y., & Sigurdsson, E. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-17313-1 · Cited by 49 · see citing works

Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer’s Disease and Other Tauopathies

Schroeder, S. K., Joly‐Amado, A., Gordon, M. N., & Morgan, D. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9637-6 · Cited by 49 · see citing works

Tau‐Tubulin Kinase 1 Expression, Phosphorylation and Co‐Localization with Phospho‐ S er422 Tau in the A lzheimer's Disease Brain

Lund, H., Cowburn, R. F., Gustafsson, E., Strömberg, K., Svensson, A., Dahllund, L., Malinowsky, D., & Sunnemark, D. (2012) · Brain Pathology · doi:10.1111/bpa.12001 · Cited by 49 · see citing works

Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases

Nozal, V., & Martı́nez, A. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.030 · Cited by 49 · see citing works

Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies

d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135774 · Cited by 48 · see citing works

Active full-length DNA Aβ42 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology

Rosenberg, R. N., Fu, M., & Lambracht‐Washington, D. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0441-4 · Cited by 48 · see citing works

NPT088 reduces both amyloid‐β and tau pathologies in transgenic mice

Levenson, J. M., Schroeter, S., Carroll, J. C., Cullen, V., Asp, E., Proschitsky, M., Chung, C. H. ‐., Gilead, S., Nadeem, M., Dodiya, H. B., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.004 · Cited by 47 · see citing works

Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies

Liu, Y.-H., Zeng, F., Wang, Y., Zhou, H., Giunta, B. N., Tan, J., & Wang, Y. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.020 · Cited by 47 · see citing works

The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration

Katsinelos, T., Tuck, B. J., Mukadam, A. S., & McEwan, W. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01139 · Cited by 44 · see citing works

Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes

Goodwin, M. S., Sinyavskaya, O., Burg, F., O’Neal, V., Ceballos‐Diaz, C., Cruz, P. E., Lewis, J. M., Giasson, B. I., Davies, P., Golde, T. E., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.007 · Cited by 42 · see citing works

Further understanding of tau phosphorylation: implications for therapy

Medina, M., & Avila, J. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1000864 · Cited by 41 · see citing works

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.: Active Tau immunotherapy

Troquier, L., Caillierez, R., Burnouf, S., Fernandez-Gomez, F., Grosjean, M.-E., Zommer, N., Sergeant, N., Schraen‐Maschke, S., Blum, D., & Buée, L. (2012) · HAL

P2‐533: Targeting phospho‐Ser422 by active Tau immunotherapy in THY‐Tau22, a suitable therapeutic approach

Troquier, L., Caillierez, R., Burnouf, S., Kervoaze, G., Grosjean, M. E., Zommer, N., Sergeant, N., Lassalle, P., Blum, D. L., & Buée, L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.1402 · Cited by 4 · see citing works

Immunotherapy approach in a mouse model of tau pathology

Troquier, L. (2011) · theses.fr (ABES)

P2‐527: Targeting hyperphosphorylated tau protein with a monoclonal antibody at an advanced stage of tau pathology improves cognition in a mouse model

Boutajangout, A., Sait, H. B. R., González‐Calle, V., & Sigurdsson, E. M. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.1396 · Cited by 3 · see citing works

Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies

Sigurdsson, E. M. (2009) · Current Alzheimer Research · doi:10.2174/156720509789207930 · Cited by 87 · see citing works